Highlights of the Day: <br />LYMPHOMA

Presented By Sonali Smith at 2014 ASCO Annual Meeting

Abstracts

Presented By Sonali Smith at 2014 ASCO Annual Meeting

Diffuse Large B-cell Lymphoma: How can we improve on R-CHOP?

Presented By Sonali Smith at 2014 ASCO Annual Meeting

Slide 4

Presented By Sonali Smith at 2014 ASCO Annual Meeting

Rituximab clearance by age and gender and study design

Presented By Sonali Smith at 2014 ASCO Annual Meeting

Slide 6

Presented By Sonali Smith at 2014 ASCO Annual Meeting

Slide 7

Presented By Sonali Smith at 2014 ASCO Annual Meeting

Diffuse Large B-cell Lymphoma: How can we improve on R-CHOP?

Presented By Sonali Smith at 2014 ASCO Annual Meeting

Synthetic lethality of lenalidomide in ABC-DLBCL and clinical proof of principle

Presented By Sonali Smith at 2014 ASCO Annual Meeting

PFS by GCB vs. non-GCB Subtype* in RCHOP Case-matched Control and R2CHOP Patients

Presented By Sonali Smith at 2014 ASCO Annual Meeting

OS by GCB vs. non-GCB Subtype in RCHOP Case-matched Control and R2CHOP Patients

Presented By Sonali Smith at 2014 ASCO Annual Meeting

PFS by Treatment Type in GCB vs. non-GCB Subtype

Presented By Sonali Smith at 2014 ASCO Annual Meeting

Abstracts

Presented By Sonali Smith at 2014 ASCO Annual Meeting

FL survival is improving for most patients

Presented By Sonali Smith at 2014 ASCO Annual Meeting

Abstract 8502:<br />246 patients with reviewed postinduction PET-CT<br />

Presented By Sonali Smith at 2014 ASCO Annual Meeting

CT & BM based response (IWC 1999 criteria)

Presented By Sonali Smith at 2014 ASCO Annual Meeting

Both PET cut-offs predictive of PFS

Presented By Sonali Smith at 2014 ASCO Annual Meeting

Postinduction PET status (cut-off ≥4) <br />and Overall Survival

Presented By Sonali Smith at 2014 ASCO Annual Meeting

Abstracts

Presented By Sonali Smith at 2014 ASCO Annual Meeting

Mantle Cell Lymphoma 2014

Presented By Sonali Smith at 2014 ASCO Annual Meeting

CHOP ± Rituximab in MCL: <br />Progression-Free Survival

Presented By Sonali Smith at 2014 ASCO Annual Meeting

Approved agents for R/R MCL<br />(Variable intensity of prior Rx among studies)

Presented By Sonali Smith at 2014 ASCO Annual Meeting

LYM-3002: Replace vincristine with bortezomib

Presented By Sonali Smith at 2014 ASCO Annual Meeting

Superior PFS by IRC with VR-CAP vs R-CHOP: 59% improvement

Presented By Sonali Smith at 2014 ASCO Annual Meeting

Peripheral Neuropathy

Presented By Sonali Smith at 2014 ASCO Annual Meeting

Conclusions – Efficacy

Presented By Sonali Smith at 2014 ASCO Annual Meeting

Abstracts

Presented By Sonali Smith at 2014 ASCO Annual Meeting

Take-home points

Presented By Sonali Smith at 2014 ASCO Annual Meeting